VBL Therapeutics Announces Novel Mechanistic Data For VB-201 – A First In Class Orally Available Anti-Inflammatory Compound That Inhibits CD14-TLR4 And TLR2-Dependent Innate Cell Activation

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the online publication of mechanistic data for VB-201 in the journal of Clinical and Experimental Immunology. The manuscript reports that VB-201, VBL's lead anti-inflammatory small molecule, inhibits toll-like receptor (TLR) 2 and TLR4 signaling in human and mouse monocytes and dendritic cells, leading to profound anti-inflammatory effect in vivo.

Help employers find you! Check out all the jobs and post your resume.